| UHC Surest Medical and Drug | Minimally Invasive Spine Surgery Procedures - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Sacral Nerve Stimulation for Urinary and Fecal Indications - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tepezza® (Teprotumumab-Trbw) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tezspire® (Tezepelumab-Ekko) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Total Artificial Disc Replacement for the Spine - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Vagus and External Trigeminal Nerve Stimulation - Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| BCBS Massachusetts | Allogeneic Hematopoietic Cell transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms | 2026-02-01 |
| BCBS Massachusetts | Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening | 2026-02-01 |
| BCBS Massachusetts | Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover | 2026-02-01 |